# Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

> **NCT05766748** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cantex Pharmaceuticals** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Azeliragon

## Key facts

- **NCT ID:** NCT05766748
- **Lead sponsor:** Cantex Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2025-02
- **Final completion:** 2025-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05766748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05766748, "Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05766748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*